Audientes (AUDNTS) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
1 Dec, 2025Executive summary
Q3 2025 was marked by delayed product deliveries and payments, resulting in limited revenue and continued liquidity pressure, but operational progress was made in China, India, South Africa, and new product development initiatives advanced.
Strategic focus shifted to dual-use hearing protection and communication products, and strengthening partnerships in key markets.
Financial highlights
Q3 2025 revenue was TDKK 42, down from TDKK 63 in Q3 2024; Q1–Q3 2025 revenue totaled TDKK 126, up from TDKK 90 year-over-year.
EBITDA for Q3 2025 was TDKK -888 (Q3 2024: TDKK -901); Q1–Q3 2025 EBITDA was TDKK -4,015 (Q1–Q3 2024: TDKK -3,930).
Net loss for Q3 2025 was TDKK -2,284 (Q3 2024: TDKK -2,513); Q1–Q3 2025 net loss was TDKK -8,577 (Q1–Q3 2024: TDKK -8,253).
Cash and cash equivalents at Q3 end were TDKK 86, up from TDKK 9 at 2024 year-end.
Equity as of September 30, 2025, was negative TDKK -3,313, with an equity ratio of -63.9%.
Outlook and guidance
Near-term progress depends on securing additional strategic and financial support; management is confident that necessary funding will be obtained.
Commercial opportunities in India, MEA, China, Japan, and Europe remain, with focus on stabilizing liquidity, securing revenue, and advancing product development.
Latest events from Audientes
- Broadened market reach and product line, but revenue missed targets and funding needs remain.AUDNTS
Q4 202416 Dec 2025 - Q1 revenue rose but losses and funding needs persisted as new markets and bond plans advanced.AUDNTS
Q1 202527 Nov 2025 - Negative equity and weak Q2 revenue offset by new orders and bond plans for H2 recovery.AUDNTS
Q2 202520 Oct 2025 - Audientes expanded in Asia, improved losses, and revised 2024 guidance amid new financing.AUDNTS
Q3 202413 Jun 2025 - H1 2024 revenue fell sharply as Audientes expanded in Asia and revised its outlook amid funding needs.AUDNTS
Q2 202413 Jun 2025